Glaxosmithkline Pharmaceuticals Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/zv1lvayi1mrh0ifscw5aegov.pdf

Key Takeaways


Revenue Growth: Volume, Not Price

Akshikar: "we remain absolutely laser focused"

Specialty & Vaccines: The New Growth Platforms

Akshikar: "this is an endurance sport in a country where adult vaccination ecosystems do not exist"

Oncology: Two Launches, One Platform


Margins: Plateau, Not Climb

Akshikar: "I won't really forecast growing up, but I think our effort will be to sustain the margins because being a significant distance that we have travelled and I think where we are today, our entire energy will be to sustain these margins as we go forward."

Unanswered Questions


Guidance & Commitments

CommitmentSpecificsTimeline
Oncology asset launchesTwo products for gynecological malignancies (endometrial cancer, ovarian cancer)End-Q1 or latest Q2 of next financial year
Adult vaccination ecosystem buildContinue investing in building ecosystem so adults above 50 can benefit from Shingles prevention; bouquet of adult antigens to followNext 12-18 months
Top-line growth ambitionRemain focused on delivering double-digit volume-led growthShort to medium term
Margin trajectoryEffort is to sustain current margins, not to grow them furtherGoing forward
New innovative assetsOncology assets and other innovative assets coming upNext 18-24 months

Key Metrics

MetricQ3 FY25
Revenue growth18% YoY
General medicines underlying volume growth11%
Specialty portfolio growth~37%
Pediatric vaccines growth15%
Total vaccines portfolio growth (including Shingrix)15% YoY; 14% for 9 months
EBITDA₹290 cr, growth of 33% YoY
EBITDA margin30.7%, improvement of 370 bps YoY
SG&A expense ratioimproved by ~2% of sales YoY
Profit After Tax growth31% YoY
PAT margin24%, improvement of 380 bps YoY
Year-to-date December revenue growth10%
Year-to-date December profit growth30%
Year-to-date December EBITDA margin30.4%, margin improvement of 450 bps
Cash conversion100% of profit into cash
Blended price increase in GenMed segment~3%
One-off reduction in employee cost₹9 cr, due to lower incentives for some brands
Trelegy growthin excess of 80% on a 12-month or quarterly basis for Q3
Trelegy category sizealmost touching ₹100 cr
Trelegy market share5–5.5%
MR productivity improvement27% in 9 months of fiscal 25
Brands above ₹100 cr each12
Towns covered by sales teamsmore than 12,000
Healthcare practitioners newly vaccinating adults2,500